Filter by: Subject

Filter by: Subject

Results Per Page:

Positron emission tomography (PET) (7)
Prostate-specific membrane antigen (PSMA) (4)
Breast cancer (3)
PET/CT (3)
Prostate carcinoma (3)
68Ga-PSMA (2)
Computed tomography (CT) (2)
Somatropin (2)
Tuberculosis (TB) (2)
225Ac-PSMA-617 (1)
68Ga-citrate (1)
Angiogenesis (1)
Behandlung (1)
Bins (1)
Bioassay (1)
Biomaterials (1)
Black South-African (BSAs) (1)
Blood–brain barrier (BBB) (1)
Bone SPECT-CT (1)
Capillary electrophoresis–mass spectrometry (CE-MS) (1)
Characterization (1)
Chelation (1)
Chemical analysis (1)
Chemical modification (1)
Chromatography (1)
Colon cancer (1)
Colorectal cancer (1)
Computerized tomography (CT) (1)
Computerized tomography' (CT) (1)
Cryptic peptides (1)
Dichroism (1)
Drug products (1)
FDG PET/CT (1)
FDG-PET (1)
FDG-PET imaging (1)
Fludeoxyglucose (FDG) (1)
Fluorine-18-Fluorodeoxyglucose (FDG) (1)
Fluorodeoxyglucose-positron emission tomography (FDG PET) (1)
Functional characterization (1)
Gastro-intestinal cancer (1)
GHR bioassay (1)
Growth hormone receptor (GHR) (1)
Highly active antiretroviral therapy (HAART) (1)
HIV infection (1)
Human growth hormone (1)
Human microbiome (1)
Immunohistochemistry (IHC) (1)
Inherent complexity (1)
Intra-tumoral heterogeneity (1)
Isomers (1)
Lipodystrophy (1)
Liquid chromatography–mass spectrometry (LC-MS) (1)
Loosening (1)
Lumbar fusion (1)
Lung lesions (1)
Mass spectrometry (1)
Medical imaging (1)
Metastasis (1)
Metastatic prostate carcinoma (1)
Microbiome (1)
Multiple substitutions (1)
Native mass spectrometries (1)
Native MS (1)
Non-prostate carcinoma (1)
NOTA modification (1)
Ovarian cancer (1)
Overall survival (OS) (1)
Patient management (1)
Patienten management (1)
Pedicle screws (1)
Peptide mapping (1)
Physico-chemical characterization (1)
Prevention (1)
Primary prostate carcinoma (PPC) (1)
Progression-free survival (PFS) (1)
Proteins (1)
PSA response (1)
Pulmonary (1)
Quality control (1)
Quorum sensing peptides (1)